Table 1.
Studies showing the sensitivity and specificity of individual tests to diagnose myasthenia
Test | Sensitivity (%) | Specificity (%) | References |
---|---|---|---|
Ice-pack test | |||
All cases of MG | 28–96 | 31–100 | [7, 8, 73, 82] |
Ocular MG | 85 | 33 | [73] |
Generalised MG | 90 | – | [73] |
Ice-pack test and SFEMG | 79 | 64 | [73] |
Ice-pack test and RNS | 24 | 92 | [73] |
Antibody tests | |||
Anti-AChR Ab | |||
All cases of MG | 50–97 | 95–100 | [16, 28, 65] |
Ocular MG | 38–75 | – | [30, 60, 72] |
Generalised MG | 73–94 | – | [30, 60, 72] |
Clustered AChR Ab | 13–66 | 100 | [10–13] |
Acetylcholinesterase Ab | 19–22 | – | [29] |
Titin receptor Ab | 20–74 | – | [27, 29] |
Ryanodine receptor Ab | 15–74 | – | [27–29] |
Anti-AChR or Anti-MuSK-Ab | 73 | – | [74] |
Anti-MuSK-Ab | 27–70b | 93–100 | [13, 19–22] |
Anti-LRP4 Ab | 3 | – | [13] |
All 4 antibodiesa | 94 | 84 | [29] |
RNS test | |||
All cases of MG | 15–92 | 73–100 | [31–33, 35, 38, 42, 43, 46, 56, 72–75] |
Ocular MG | 14–67 | 91 | [30, 31, 36, 60, 65, 72, 73] |
Generalised MG | 32–94 | – | [30, 31, 36, 60, 65, 72, 73] |
SFEMG test | |||
All cases of MG | 64–100 | 22–97 | [32, 42, 45, 48–50, 59–61, 65, 73–75, 87] |
Ocular MG | 73–100 | 22–100c | [32, 49, 52, 60, 62, 72–74] |
Generalised MG | 85–99 | 91–100c | [32, 49, 60, 62, 72–74] |
RNS and SFEMG tests | 18 | 91 | [73] |
Edrophonium test | |||
All cases of MG | 50–92 | 97 | [67, 79] |
Ocular MG | 92 | 97 | |
Generalised MG | 88 | 97 | |
Neostigmine test | |||
All cases of MG | 83 | 97 | [82] |
Ocular MG | 93 | – | [30] |
Generalised MG | 98 | – | [30] |
oVEMP test | 63–89 | 64–100 | [87] |
oVEMP Ocular vestibular-evoked myogenic potentials, MG myasthenia gravis, SFEMG single-fibre electromyography, RNS repetitive nerve stimulation, MuSK muscle-specific kinase, Ab antibody, AChR acetylcholine receptor, LRP4 LDL receptor-related protein 4, RyR ryanodine receptor
aAll 4 antibodies = Acetylcholine receptor, acetylcholinesterase, titin and ryanodine receptor antibodies
bIn those who are seronegative for anti-AChR antibody
cDepending on control population